Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
MONDAY, May 12, 2025 (HealthDay News) — The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according to...
Read more